Imperial Innovations diversified investment portfolio includes seven unquoted oncology-focused companies (excluding the recently announced Artios Pharma), which represent 20% (72m) of total portfolio value. These companies (six in therapeutics, one in medtech) are focused on improving cancer care through the development of proprietary technology platforms, therapeutics and diagnostics. The size of recent funding rounds led by Innovations points to the increasing momentum in and maturity of th
27 Sep 2016
Shining a light on the oncology portfolio
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Shining a light on the oncology portfolio
Touchstone Innovations (IVO:LON) | 0 0 0.0% | Mkt Cap: 508.5m
- Published:
27 Sep 2016 -
Author:
Lala Gregorek -
Pages:
32
Imperial Innovations diversified investment portfolio includes seven unquoted oncology-focused companies (excluding the recently announced Artios Pharma), which represent 20% (72m) of total portfolio value. These companies (six in therapeutics, one in medtech) are focused on improving cancer care through the development of proprietary technology platforms, therapeutics and diagnostics. The size of recent funding rounds led by Innovations points to the increasing momentum in and maturity of th